Methods for the surveillance, diagnosis and screening of bladder cancer

A method for the treatment of bladder cancer, wherein said method comprises the steps of:

• a) detecting, in a biological sample obtained from a subject, mutations in the FGFR3 gene;
• b) measuring, in the same biological sample as that used in step a), the degree of methylation of SEPTIN 9 and HS3ST2,
• c) determining, in view of the results obtained in steps a) and b), whether the subject has bladder cancer;
• and
• d) treating the subject identified as having a bladder cancer in step c) with an anticancer treatment,
• wherein said mutations are:
• 742C→T, 746C→G, 1114G→T, and 1124A→G by reference to the nucleotide numbers of SEQ ID NO:
• 1;
• or
• Arg248Cys, Ser249Cys, Gly372Cys, and Tyr375Cys, by reference to the amino acid numbers of SEQ ID NO:
• 2.

An analytical method comprising the steps of:

• a) detecting, in a biological sample obtained from a subject, mutations in the FGFR3 gene;
• and
• b) measuring, in the same biological sample as that used in step a), the degree of methylation of SEPTIN 9 and HS3ST2;
• wherein said mutations are the following mutations:
• 742C→T, 746C→G, 1114G→T, and 1124A→G by reference to the nucleotide numbers of SEQ ID NO:
• 1;
• or
• Arg248Cys, Ser249Cys, Gly372Cys, and Tyr375Cys, by reference to the amino acid numbers of SEQ ID NO:
• 2.